CRVS (Corvus Pharmaceuticals) EBIT per Share : $-0.46 (TTM As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Corvus Pharmaceuticals EBIT per Share?

Corvus Pharmaceuticals's EBIT per Share for the three months ended in Mar. 2025 was $-0.13. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.46.

During the past 3 years, the average EBIT per Share Growth Rate was 21.20% per year. During the past 5 years, the average EBIT per Share Growth Rate was 25.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Corvus Pharmaceuticals's EBIT per Share or its related term are showing as below:

CRVS' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -38.4 Med: 19.8 Max: 31
Current: 21.2

During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of Corvus Pharmaceuticals was 31.00% per year. The lowest was -38.40% per year. And the median was 19.80% per year.

CRVS's 3-Year EBIT Growth Rate is ranked better than
64.23% of 1219 companies
in the Biotechnology industry
Industry Median: 9.3 vs CRVS: 21.20

Corvus Pharmaceuticals's EBIT for the three months ended in Mar. 2025 was $-9.92 Mil.

Corvus Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Corvus Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corvus Pharmaceuticals EBIT per Share Chart

Corvus Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT per Share

Get a 7-Day Free Trial

-1.48

-0.92

-0.70

-0.49

-0.45

Corvus Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EBIT per Share	Get a 7-Day Free Trial															-0.13	-0.10	-0.11	-0.12	-0.13

Corvus Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Corvus Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-27.548	/	60.985
=	-0.45

Corvus Pharmaceuticals's EBIT per Share for the quarter that ended in Mar. 2025 is calculated as

	EBIT per Share		(Q: Mar. 2025 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-9.922	/	75.153
=	-0.13

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.46

Corvus Pharmaceuticals (NAS:CRVS) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Corvus Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Corvus Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Corvus Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corvus Pharmaceuticals Inc (NAS:CRVS) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

C17:Germany

Address

901 Gateway Boulevard, Third Floor, South San Francisco, CA, USA, 94080

Website

https://www.corvuspharma.com

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Executives

William Benton Jones	officer: See Remarks	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Miller Richard A Md	director, officer: President and CEO	PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Linda S Grais	director	86 ALEJANDRA AVE, ATHERTON CA 94027
Leiv Lea	officer: Chief Financial Officer	PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Peter A. Thompson	director, 10 percent owner	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Edith P. Mitchell	director	1640 MARENGO ST., LOS ANGELES CA 90033
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Mehrdad Mobasher	officer: Chief Medical Officer	863 MITTEN ROAD, BURLINGAME CA 94010
Adams Street Partners Llc	10 percent owner	ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807
Terry P Gould	director, 10 percent owner	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Joseph J Buggy	officer: EVP Discovery Research	CORVUS PHARMACEUTICALS, INC., 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Daniel W. Hunt	officer: SVP, Chief Business Officer	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Erik J. Verner	officer: V.P., Chemistry Research	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010